摘 要 腦血管痙攣（cerebral vasospasm, CVS）是蛛網(wǎng)膜下腔出血（subarachnoid hemorrhage, SAH）最常見的高危并發(fā)癥之一, 是SAH患者致死和致殘的主要原因。有證據(jù)表明, 內(nèi)皮素信號(hào)系統(tǒng)在SAH后CVS和遲發(fā)性腦缺血損傷的病理生理過程中起重要作用, 因而內(nèi)皮素受體拮抗劑在CVS治療中的意義備受關(guān)注?？死梗–lazosentan）是一種選擇性內(nèi)皮素受體拮抗劑, 動(dòng)物實(shí)驗(yàn)和臨床試驗(yàn)都表明其可有效緩解SAH引發(fā)的CVS, 故有望成為腦血管痙攣的新型治療藥物。

Abstract: Cerebral vasospasm (CVS) is one of the most common complications with high risk following subarachnoid hemorrhage (SAH), and a leading cause of death and disability in SAH patients. There are evidences shown that endothelin pathways play key roles in the CVS following SAH and late cerebral ischemic injury, thus the therapeutic significance of endothelin receptor antagonists in CVS attract widely attention. Clazosentan, a selective endothelin receptor antagonist, has been proved to be effective for SAH-induced CVS in animal experiments and clinical trials. It is expected to become a new drug for treatment of CVS.